

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) An SRSV detection kit comprising polyclonal antibodies against SRSV-related viruses, wherein said polyclonal antibodies are defined in (a) to(k) as follows:

(a) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:1 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(b) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:2 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(c) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:3 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(d) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:4 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(e) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:5 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(f) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:6 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(g) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:7 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(h) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:8 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(i) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:9 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(j) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:10 ~~and peptides having at least 80% homology with said amino acid sequence,~~ and

(k) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:11 ~~and peptides having at least 80% homology with said amino acid sequence;~~ and

wherein said polyclonal antibodies react specifically with the peptides as defined in (a) to (k) above and do not cross-react with any of the other peptides represented by SEQ ID NOs:1-11 or a peptide having 80% homology therewith, ~~except as defined in (a) to (k) above.~~

2. (Original) An SRSV detection kit according to claim 1, wherein said antibodies have been prepared by immunizing with virus-like particles.

3. (Original) An SRSV detection kit according to claim 1, which is useful for distinguishing serotype of SRSVs.

4. (Currently Amended) An SRSV detection kit for discriminating genogroup of SRSVs, the kit comprising polyclonal antibodies against SRSV-related viruses, wherein said polyclonal antibodies are defined in (a) to (d) as follows:

(a) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:1 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(b) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:2 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(c) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:3 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(d) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:4 ~~and peptides having at least 80% homology with said amino acid sequence;~~ and

wherein said polyclonal antibodies react specifically with the peptides as defined in (a) to (d) above and do not cross-react with any of the other peptides represented by SEQ ID NOs:1-4 or a peptide having 80% homology therewith, ~~except as defined in (a) to (d) above.~~

5. (Currently Amended) An SRSV detection kit for discriminating genogroup of SRSVs, the kit comprising polyclonal antibodies against SRSV-related viruses, wherein said polyclonal antibodies are defined in (e) to (k) as follows:

(e) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:5 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(f) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:6 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(g) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:7 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(h) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:8 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(i) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:9 ~~and peptides having at least 80% homology with said amino acid sequence,~~

(j) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:10 ~~and peptides having at least 80% homology with said amino acid sequence, and~~

(k) a polyclonal antibody directed against a peptide having an amino acid sequence represented by SEQ ID NO:11 ~~and peptides having at least 80% homology with said amino acid sequence; and~~

wherein said polyclonal antibodies react specifically with the peptides as defined in (e) to (k) above and do not cross-react with any of the other peptides represented by SEQ ID NOs:5-11 or a peptide having 80% homology therewith, ~~except as defined in (e) to (k) above.~~

6. (Previously Presented) An SRSV detection kit according to claim 1, wherein SRSVs are captured with solid-phase antibody carriers having said antibodies immobilized thereon.

Claims 7-10 (Cancelled)

11. (Previously Presented) An SRSV detection kit according to claim 4, wherein SRSVs are captured with solid-phase antibody carriers having said antibodies immobilized thereon.

12. (Previously Presented) An SRSV detection kit according to claim 5, wherein SRSVs are captured with solid-phase antibody carriers having said antibodies immobilized thereon.

13. (Previously Presented) A method of detecting the presence of an SRSV-related virus, comprising

obtaining a sample comprising a candidate SRSV-related virus;
contacting said sample with the SRSV detection kit according to Claim 1; and
measuring the absence or presence of an interaction with one or more polyclonal antibodies in said SRSV detection kit.

14. (Previously Presented) The method of claim 13, wherein said measuring is by an immunoassay.

15. (Previously Presented) The method of claim 14, wherein said immunoassay comprises individually immobilizing polyclonal antibodies (a) through (k).

16. (Previously Presented) A method of genogrouping SRSV-related viruses, comprising

- obtaining a sample comprising a candidate SRSV-related virus;
- contacting said sample with the SRSV detection kit according to Claim 4; and
- measuring the absence or presence of an interaction with one or more polyclonal antibodies in said SRSV detection kit.

17. (Previously Presented) The method of claim 16, wherein said measuring is by an immunoassay.

18. (Previously Presented) The method of claim 17, wherein said immunoassay comprises individually immobilizing polyclonal antibodies (a) through (d).

19. (Previously Presented) A method of genogrouping SRSV-related viruses, comprising

- obtaining a sample comprising a candidate SRSV-related virus;
- contacting said sample with the SRSV detection kit according to Claim 5; and
- measuring the absence or presence of an interaction with one or more polyclonal antibodies in said SRSV detection kit.

20. (Previously Presented) The method of claim 19, wherein said measuring is by an immunoassay.

21. (Previously Presented) The method of claim 20, wherein said immunoassay comprises individually immobilizing polyclonal antibodies (e) through (k).